Matteo Bassetti, Department of Health Sciences (DISSAL), University of Genoa; Clinica Malattie Infettive, San Martino Policlinico Hospital - IRCCS for Oncology and Neurosciences, Genoa, Italy
Silvia Dettori, Clinica Malattie Infettive, San Martino Policlinico Hospital - IRCCS for Oncology and Neurosciences, Genoa, Italy
Federica Briano, Clinica Malattie Infettive, San Martino Policlinico Hospital - IRCCS for Oncology and Neurosciences, Genoa, Italy
Laura Mezzogori, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
Pneumonia remains a leading cause of morbidity and mortality worldwide, placing a significant burden on healthcare systems due to hospitalizations and the demand for medical resources. In recent years, new drugs have been developed to improve the effectiveness and safety of empirical treatment for community-acquired pneumonia and both empirical and targeted treatments for hospital-acquired and ventilator-associated pneumonia, including those caused by highly antibiotic-resistant pathogens. The aim of this narrative review is to focus on recently approved drugs for pneumonia and provide an overview of promising future therapeutic options.
